Henan Taloph Pharmaceutical Stock (600222) Fundamentals 2026 — P/E 63.4x, Revenue Analysis | SniperIQ
Henan Taloph Pharmaceutical Stock (600222) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥3.9B, trading at ¥6.98 on the SHH. This SniperIQ fundamentals page covers Henan Taloph Pharmaceutical Stock's valuation (P/E 63.4x, P/B 2.4x), profitability (net margin 3.4%), revenue (¥1.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Henan Taloph Pharmaceutical Stock's market cap?
Henan Taloph Pharmaceutical Stock (600222) has a market capitalization of approximately ¥3.9B, trading at ¥6.98 on the SHH. Market cap moves with the live share price.
What is Henan Taloph Pharmaceutical Stock's P/E ratio?
Henan Taloph Pharmaceutical Stock's trailing twelve-month P/E ratio is 63.4x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Henan Taloph Pharmaceutical Stock?
Henan Taloph Pharmaceutical Stock runs a net profit margin of 3.4%, a gross margin of 27.9%, and an operating margin of 5.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Henan Taloph Pharmaceutical Stock generate?
Henan Taloph Pharmaceutical Stock reported revenue of ¥1.8B for fiscal year 2025, with net income of ¥60M and earnings per share (EPS) of 0.11. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Henan Taloph Pharmaceutical Stock pay a dividend?
Henan Taloph Pharmaceutical Stock offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Henan Taloph Pharmaceutical Stock financially healthy?
Henan Taloph Pharmaceutical Stock carries a debt-to-equity ratio of 0.70x and a current ratio of 1.26x, with a market beta of 0.69. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Henan Taloph Pharmaceutical Stock a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Henan Taloph Pharmaceutical Stock (600222) the key facts are: market cap ¥3.9B, P/E 63.4x, revenue ¥1.8B, 52-week range 6.06-9.44. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Henan Taloph Pharmaceutical Stock's full fundamentals live
Get Henan Taloph Pharmaceutical Stock's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.